Source: Eur Respir J 2013; 41: 246-247



Rating:

Share or cite this content

Citations should be made in the following way:
Tissot Claire, Carsin Ania, Freymond Nathalie, Pacheco Yves, Devouassoux Gilles. Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy. Eur Respir J 2013; 41: 246-247

Member's Comments

No comment yet.

Related content which might interest you: Cytotoxic T cell lymphocyte-associated 4 (CTLA4) polymorphisms in UK sarcoidosis patients Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008 The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma Source: Eur Respir J 2001; 18: 45-52 Year: 2001 Neutrophils, interleukin-17A and lung disease Source: Eur Respir J 2005; 25: 159-172 Year: 2005 Reversing the suppression of T-cells: the role of monoclonal antibodies Source: International Congress 2015 – Stop immune tolerance in lung cancer! Year: 2015 Massive monoclonal expansion of CD4 T-cells specific for a Mycobacterium tuberculosis ESAT-6 peptide Source: Eur Respir J 2012; 40: 152-160 Year: 2012 Efficacy and safety of anti-PD-L1 antibody in NSCLC patients who previously treated with anti PD-1 antibodies Source: International Congress 2019 – Treatment of lung cancer Year: 2019 Allergen specific immunotherapy induces T-cell anergy via upregulating CTLA-4 and downregulating CD86 in a murine OVA-sensitized model Source: Eur Respir J 2004; 24: Suppl. 48, 349s Year: 2004 Recognition of pleural mesothelioma by mucin-1(950–958)/human leukocyte antigen A*0201-specific CD8+ T-cells Source: Eur Respir J 2011; 38: 1117-1126 Year: 2011 PP129 – Safety evaluation of cancer immunotherapy in a lung-on-chip model: the therapeutic FOLR1 targeting T Cell Bispecific antibody Source: ERS Lung Science Conference 2021 Year: 2021 A patient-derived lung-on-chip model to evaluate on-target/off-tumour toxicity of the therapeutic FOLR1-targeting T-Cell Bispecific antibody Source: Virtual Congress 2021 – In vitro modelling of lung disease: reach out to the next dimension Year: 2021 Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions Source: Eur Respir J 2003; 21: 799-803 Year: 2003 Rapid reversal of radiation-induced murine pneumonitis by treatment with the anti-CTGF monoclonal antibody FG-3019 Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases Year: 2011 Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021 CTLA-4-mediated regulatory phenotype of T-cells in tolerant lung recipients Source: Eur Respir J 2008; 31: 1167-1176 Year: 2008 Impact of age on the efficacy of anti-IL-5 monoclonal antibodies in severe asthmatics Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Cure bronchiectasis associated with anti-neutrophil cytoplasmatic antibodies (ANCA) with immunosuppressive therapy Source: International Congress 2015 – New insights into lung disease pathogenesis Year: 2015 Cytotoxic T-lymphocyte antigen 4 gene polymorphisms in sarcoidosis Source: Annual Congress 2005 - Progresses in granolomatous lung disease Year: 2005 Late Breaking Abstract - Anti-IL-4 and anti-IL-13 dual vaccination using Kinoid technology prevents development of allergic asthma in mice Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Pre-transplant soluble CD30 is a stronger predictor of BOS than anti-HLA antibodies occurring after lung transplantation Source: Annual Congress 2007 - New insights into clinical lung transplantation Year: 2007 Dendritic cells stimulated by agonistic anti-CD40 mAb could elicit activation of lung cancer patients’ autologous cytotoxic T lymphocytes Source: Eur Respir J 2004; 24: Suppl. 48, 673s Year: 2004